Great Ormond Street Hospital for Children NHS Foundation Trust
gosh.nhs.ukLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
82
Active
12
Phase 3
2
Total enrollment
18,800
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lentiviral vector transduced CD34+ cells | — | — | — | — | 2 | ||
| Cryopreserved BE CAR33 T Cells | — | — | — | — | — | 1 | |
| Indocyanine Green | — | — | — | — | — | 1 |
Next readouts
- 2026-06-01
- 2026-08
- 2028-08
- 2029-04-01
Top conditions
- Cystic Fibrosis3
- Epilepsy3
- Critical Care2
- Moyamoya2
- Adenosine Deaminase Deficiency2
- Epilepsy, Focal2
- Dilated Cardiomyopathy2
- Duchenne Muscular Dystrophy2
Frequently asked questions about Great Ormond Street Hospital for Children NHS Foundation Trust
- How many clinical trials does Great Ormond Street Hospital for Children NHS Foundation Trust have on ClinicalTrials.gov?
- Great Ormond Street Hospital for Children NHS Foundation Trust is listed as the lead sponsor on 82 clinical trials in ClinicalTrials.gov, 12 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Great Ormond Street Hospital for Children NHS Foundation Trust's trials are in Phase 3?
- 2 of Great Ormond Street Hospital for Children NHS Foundation Trust's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Great Ormond Street Hospital for Children NHS Foundation Trust focus on?
- Great Ormond Street Hospital for Children NHS Foundation Trust's most-studied conditions on ClinicalTrials.gov are Cystic Fibrosis, Epilepsy, Critical Care, Moyamoya, Adenosine Deaminase Deficiency.
- When are Great Ormond Street Hospital for Children NHS Foundation Trust's next clinical trial readouts?
- Great Ormond Street Hospital for Children NHS Foundation Trust has 4 upcoming primary-completion readouts tracked here; the soonest is “Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation”, expected around 2026-06-01.